ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Bevacizumab Monoclonal Antibody Biosimilar Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-25N14573
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Bevacizumab Monoclonal Antibody Biosimilar Market Research Report 2023
BUY CHAPTERS

Global Bevacizumab Monoclonal Antibody Biosimilar Market Research Report 2025

Code: QYRE-Auto-25N14573
Report
May 2025
Pages:73
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Celltrion
Amneal
Pfizer Inc
Amgen Inc

Bevacizumab Monoclonal Antibody Biosimilar Market Size

The global market for Bevacizumab Monoclonal Antibody Biosimilar was valued at US$ 1049 million in the year 2024 and is projected to reach a revised size of US$ 356 million by 2031, growing at a CAGR of -14.5% during the forecast period.

Bevacizumab Monoclonal Antibody Biosimilar Market

Bevacizumab Monoclonal Antibody Biosimilar Market

Avastin Biosimilar is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.
North American market for Bevacizumab Monoclonal Antibody Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Bevacizumab Monoclonal Antibody Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Bevacizumab Monoclonal Antibody Biosimilar include Celltrion, Amneal, Pfizer, Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Bevacizumab Monoclonal Antibody Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bevacizumab Monoclonal Antibody Biosimilar.
The Bevacizumab Monoclonal Antibody Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Bevacizumab Monoclonal Antibody Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bevacizumab Monoclonal Antibody Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Bevacizumab Monoclonal Antibody Biosimilar Market Report

Report Metric Details
Report Name Bevacizumab Monoclonal Antibody Biosimilar Market
Accounted market size in year US$ 1049 million
Forecasted market size in 2031 US$ 356 million
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • 400mg
  • 100mg
Segment by Application
  • Cancer
  • Wet Age-related Macular Degeneration
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Celltrion, Amneal, Pfizer, Amgen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Bevacizumab Monoclonal Antibody Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Bevacizumab Monoclonal Antibody Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

What is the Bevacizumab Monoclonal Antibody Biosimilar Market size in 2031?

Ans: The Bevacizumab Monoclonal Antibody Biosimilar Market size in 2031 will be US$ 356 million.

Who are the main players in the Bevacizumab Monoclonal Antibody Biosimilar Market report?

Ans: The main players in the Bevacizumab Monoclonal Antibody Biosimilar Market are Celltrion, Amneal, Pfizer, Amgen

What are the Application segmentation covered in the Bevacizumab Monoclonal Antibody Biosimilar Market report?

Ans: The Applications covered in the Bevacizumab Monoclonal Antibody Biosimilar Market report are Cancer, Wet Age-related Macular Degeneration, Other

What are the Type segmentation covered in the Bevacizumab Monoclonal Antibody Biosimilar Market report?

Ans: The Types covered in the Bevacizumab Monoclonal Antibody Biosimilar Market report are 400mg, 100mg

Recommended Reports

Biosimilar Monoclonal Antibodies

VEGF Inhibitors & Anti-VEGF

Comprehensive Biosimilars Market

1 Bevacizumab Monoclonal Antibody Biosimilar Market Overview
1.1 Product Definition
1.2 Bevacizumab Monoclonal Antibody Biosimilar by Type
1.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Value Comparison by Type (2024 VS 2031)
1.2.2 400mg
1.2.3 100mg
1.3 Bevacizumab Monoclonal Antibody Biosimilar by Application
1.3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Value by Application (2024 VS 2031)
1.3.2 Cancer
1.3.3 Wet Age-related Macular Degeneration
1.3.4 Other
1.4 Global Bevacizumab Monoclonal Antibody Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue 2020-2031
1.4.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales 2020-2031
1.4.3 Global Bevacizumab Monoclonal Antibody Biosimilar Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Bevacizumab Monoclonal Antibody Biosimilar Market Competition by Manufacturers
2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Manufacturers (2020-2025)
2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Bevacizumab Monoclonal Antibody Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, Product Type & Application
2.7 Global Key Manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, Date of Enter into This Industry
2.8 Global Bevacizumab Monoclonal Antibody Biosimilar Market Competitive Situation and Trends
2.8.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Bevacizumab Monoclonal Antibody Biosimilar Players Market Share by Revenue
2.8.3 Global Bevacizumab Monoclonal Antibody Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Bevacizumab Monoclonal Antibody Biosimilar Market Scenario by Region
3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Region: 2020-2031
3.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Region: 2020-2025
3.2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Region: 2026-2031
3.3 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region: 2020-2031
3.3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region: 2020-2025
3.3.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region: 2026-2031
3.4 North America Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.4.1 North America Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2020-2031)
3.4.3 North America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.5.1 Europe Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2020-2031)
3.5.3 Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Region
3.6.1 Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales by Region (2020-2031)
3.6.3 Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2020-2031)
3.7.3 Latin America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2020-2031)
3.8.3 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2020-2031)
4.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2020-2025)
4.1.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2026-2031)
4.1.3 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2020-2031)
4.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Type (2020-2031)
4.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Type (2020-2025)
4.2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Type (2026-2031)
4.2.3 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2020-2031)
4.3 Global Bevacizumab Monoclonal Antibody Biosimilar Price by Type (2020-2031)
5 Segment by Application
5.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2020-2031)
5.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2020-2025)
5.1.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2026-2031)
5.1.3 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2020-2031)
5.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Application (2020-2031)
5.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Application (2020-2025)
5.2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Application (2026-2031)
5.2.3 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2020-2031)
5.3 Global Bevacizumab Monoclonal Antibody Biosimilar Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Celltrion
6.1.1 Celltrion Company Information
6.1.2 Celltrion Description and Business Overview
6.1.3 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Product Portfolio
6.1.5 Celltrion Recent Developments/Updates
6.2 Amneal
6.2.1 Amneal Company Information
6.2.2 Amneal Description and Business Overview
6.2.3 Amneal Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Amneal Bevacizumab Monoclonal Antibody Biosimilar Product Portfolio
6.2.5 Amneal Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Company Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Amgen Bevacizumab Monoclonal Antibody Biosimilar Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bevacizumab Monoclonal Antibody Biosimilar Industry Chain Analysis
7.2 Bevacizumab Monoclonal Antibody Biosimilar Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bevacizumab Monoclonal Antibody Biosimilar Production Mode & Process Analysis
7.4 Bevacizumab Monoclonal Antibody Biosimilar Sales and Marketing
7.4.1 Bevacizumab Monoclonal Antibody Biosimilar Sales Channels
7.4.2 Bevacizumab Monoclonal Antibody Biosimilar Distributors
7.5 Bevacizumab Monoclonal Antibody Biosimilar Customer Analysis
8 Bevacizumab Monoclonal Antibody Biosimilar Market Dynamics
8.1 Bevacizumab Monoclonal Antibody Biosimilar Industry Trends
8.2 Bevacizumab Monoclonal Antibody Biosimilar Market Drivers
8.3 Bevacizumab Monoclonal Antibody Biosimilar Market Challenges
8.4 Bevacizumab Monoclonal Antibody Biosimilar Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Celltrion
Amneal
Pfizer Inc
Amgen Inc
List of Tables
 Table 1. Global Bevacizumab Monoclonal Antibody Biosimilar Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Bevacizumab Monoclonal Antibody Biosimilar Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Bevacizumab Monoclonal Antibody Biosimilar Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Bevacizumab Monoclonal Antibody Biosimilar Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Bevacizumab Monoclonal Antibody Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, Product Type & Application
 Table 12. Global Key Manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Bevacizumab Monoclonal Antibody Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bevacizumab Monoclonal Antibody Biosimilar as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Bevacizumab Monoclonal Antibody Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Region (2020-2025) & (K Units)
 Table 18. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2020-2025)
 Table 19. Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Region (2026-2031) & (K Units)
 Table 20. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2026-2031)
 Table 21. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2020-2025)
 Table 23. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2026-2031)
 Table 25. North America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 27. North America Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 28. North America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units) by Type (2020-2025)
 Table 51. Global Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units) by Type (2026-2031)
 Table 52. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2020-2025)
 Table 53. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2026-2031)
 Table 54. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2020-2025)
 Table 57. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2026-2031)
 Table 58. Global Bevacizumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Bevacizumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units) by Application (2020-2025)
 Table 61. Global Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units) by Application (2026-2031)
 Table 62. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2020-2025)
 Table 63. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2026-2031)
 Table 64. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2020-2025)
 Table 67. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2026-2031)
 Table 68. Global Bevacizumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Bevacizumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Application (2026-2031)
 Table 70. Celltrion Company Information
 Table 71. Celltrion Description and Business Overview
 Table 72. Celltrion Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Celltrion Bevacizumab Monoclonal Antibody Biosimilar Product
 Table 74. Celltrion Recent Developments/Updates
 Table 75. Amneal Company Information
 Table 76. Amneal Description and Business Overview
 Table 77. Amneal Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Amneal Bevacizumab Monoclonal Antibody Biosimilar Product
 Table 79. Amneal Recent Developments/Updates
 Table 80. Pfizer Company Information
 Table 81. Pfizer Description and Business Overview
 Table 82. Pfizer Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Pfizer Bevacizumab Monoclonal Antibody Biosimilar Product
 Table 84. Pfizer Recent Developments/Updates
 Table 85. Amgen Company Information
 Table 86. Amgen Description and Business Overview
 Table 87. Amgen Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Amgen Bevacizumab Monoclonal Antibody Biosimilar Product
 Table 89. Amgen Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Bevacizumab Monoclonal Antibody Biosimilar Distributors List
 Table 93. Bevacizumab Monoclonal Antibody Biosimilar Customers List
 Table 94. Bevacizumab Monoclonal Antibody Biosimilar Market Trends
 Table 95. Bevacizumab Monoclonal Antibody Biosimilar Market Drivers
 Table 96. Bevacizumab Monoclonal Antibody Biosimilar Market Challenges
 Table 97. Bevacizumab Monoclonal Antibody Biosimilar Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Bevacizumab Monoclonal Antibody Biosimilar
 Figure 2. Global Bevacizumab Monoclonal Antibody Biosimilar Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Bevacizumab Monoclonal Antibody Biosimilar Market Share by Type: 2024 & 2031
 Figure 4. 400mg Product Picture
 Figure 5. 100mg Product Picture
 Figure 6. Global Bevacizumab Monoclonal Antibody Biosimilar Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Bevacizumab Monoclonal Antibody Biosimilar Market Share by Application: 2024 & 2031
 Figure 8. Cancer
 Figure 9. Wet Age-related Macular Degeneration
 Figure 10. Other
 Figure 11. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Bevacizumab Monoclonal Antibody Biosimilar Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Bevacizumab Monoclonal Antibody Biosimilar Sales (2020-2031) & (K Units)
 Figure 14. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price (US$/Unit) & (2020-2031)
 Figure 15. Bevacizumab Monoclonal Antibody Biosimilar Report Years Considered
 Figure 16. Bevacizumab Monoclonal Antibody Biosimilar Sales Share by Manufacturers in 2024
 Figure 17. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Bevacizumab Monoclonal Antibody Biosimilar Players: Market Share by Revenue in Bevacizumab Monoclonal Antibody Biosimilar in 2024
 Figure 19. Bevacizumab Monoclonal Antibody Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Bevacizumab Monoclonal Antibody Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2020-2031)
 Figure 22. North America Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 23. United States Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2020-2031)
 Figure 26. Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2020-2031)
 Figure 34. China Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2020-2031)
 Figure 42. Latin America Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of Bevacizumab Monoclonal Antibody Biosimilar by Type (2020-2031)
 Figure 52. Global Revenue Market Share of Bevacizumab Monoclonal Antibody Biosimilar by Type (2020-2031)
 Figure 53. Global Bevacizumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Type (2020-2031)
 Figure 54. Global Sales Market Share of Bevacizumab Monoclonal Antibody Biosimilar by Application (2020-2031)
 Figure 55. Global Revenue Market Share of Bevacizumab Monoclonal Antibody Biosimilar by Application (2020-2031)
 Figure 56. Global Bevacizumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Application (2020-2031)
 Figure 57. Bevacizumab Monoclonal Antibody Biosimilar Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Avastin Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biosimilar Bevacizuma Market Research Report 2024
Global Avastin Bevacizumab Biosimilars Market Research Report 2024
Global Monoclonal Antibody VEGF Inhibitors Market Research Report 2024
Global Bevacizumab Generics Market Research Report 2024
Global Bevacizumab Market Insights Forecast to 2030
Global Ranibizumab Drugs and Biosimilars Market Research Report 2024
Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Monoclonal Antibody Anti VEGF Ophthalmic Drugs Market Research Report 2024
Global Anti VEGF Therapy for Cancer Market Research Report 2024
Herceptin Trastuzumab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Raibizumab Biosimilars Market Research Report 2025
Global Monoclonal antibodies mAbs Biosimilars Market Research Report 2024
Global VEGF Inhibitors for Cancer Market Research Report 2024
Global Biosimilar Antibodies Market Research Report 2024
Global Rituximab Biosimilars Market Research Report 2025
Bevacizumab Biosimilar Market
Oncology Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global VEGF Inhibitors Market Research Report 2024
Lucentis Ranibizumab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions